Telehealth Weight-Loss Programs, Ranked by What They Actually Cost
Ranked strictly by monthly cost, compounded programs sit at the bottom, often advertising flat prices in the low hundreds, while brand medication through a telehealth service sits at the top, frequently above a thousand dollars a month before insurance or manufacturer self-pay applies. But that ranking hides the real story. The cheapest option is a compounded product that is not FDA-approved, and the advertised entry price is rarely the price you pay six months in. Cost only means something once you know what sits behind it.
What actually drives the monthly number?
The platform matters less than most people assume. Ro, Hims and Hers, Henry Meds, LillyDirect, and NovoCare all exist to connect a patient with a prescription and a pharmacy, and the biggest cost lever is which pharmacy fills it. A brand product like Zepbound or Wegovy carries a list price above a thousand dollars a month. A compounded version of the same active molecule can be a fraction of that, because it skips the approval process and the trial program that generated its evidence.
That gap is why compounded programs dominate the cheap end of any ranking. It is also why a strict cost ranking is misleading on its own. You are not comparing two versions of the same thing. You are comparing an FDA-approved medication against a preparation that has not been through that review.
Why is the advertised price rarely the real price?
Most low headline figures apply to the starting dose, the first month, or a prepaid multi-month plan. GLP-1 dosing steps up over time, and many programs raise the monthly charge as the dose climbs. Some add a separate membership or consultation fee. A price that looks like a clear winner in month one can converge toward the middle of the field by month four.
This is the single most common blind spot in program comparisons, and it is where a lot of published reviews fall short. If you read Medvi reviews or the equivalent for any competitor, watch whether the writer priced the full titration schedule or just the entry tier. The sustainable monthly cost, at the dose you expect to stay on, is the figure worth ranking.
How do the program types compare?
| Program type | Typical monthly cost | What you are getting | Main limitation |
|---|---|---|---|
| Compounded telehealth | Low to mid hundreds | Compounded semaglutide or tirzepatide, flat cash pricing | Not an FDA-approved product |
| Brand via telehealth | Often above a thousand | Wegovy or Zepbound with a prescription | Price and access depend on coverage |
| Manufacturer direct (LillyDirect, NovoCare) | Mid hundreds and up for cash self-pay | Brand product at a set self-pay price | Refill-timing and dose conditions |
| Covered through insurance | Copay only, if covered | Brand product on formulary | Many plans exclude the category |
Where does the compounded discount come from?
It comes from skipping the approval process, not from a smarter supply chain. Compounded drugs are prepared by pharmacies under specific legal conditions, and the FDA has been explicit that these products are not reviewed for safety, effectiveness, or quality the way approved drugs are. Pharmacovigilance work using the FDA adverse event reporting system has flagged safety signals tied to compounded GLP-1 products, and a poison control case series documented dosing errors when patients measured their own compounded semaglutide. Clinical reviews aimed at prescribers have laid out what to check before recommending these products at all.
None of that makes compounded medication automatically wrong for a given person. It does mean the price advantage is not free. You are trading regulatory assurance for cost predictability, and that trade belongs with a prescriber who knows your history, not a checkout page.
Does the drug you get change the value?
Yes, and this is where a flat cost ranking gets more honest. Tirzepatide and semaglutide are not interchangeable in outcome. In SURMOUNT-1, tirzepatide produced mean weight reductions well beyond what semaglutide trials have shown, and a later head-to-head comparison of the two molecules favored tirzepatide for weight loss. Maintenance data from SURMOUNT-4 showed that stopping the drug tends to reverse the loss, and SURMOUNT-CN confirmed the effect in a different population. If a cheaper program is dispensing the less effective molecule, the lower price is buying a different result.
Where do specific programs land?
Manufacturer routes like LillyDirect and NovoCare are the honest floor for brand product without insurance, since they sell at a set self-pay price with conditions attached. Ro and Hims and Hers span both worlds, offering brand and compounded paths depending on eligibility and stock. Henry Meds built its model around compounded flat pricing. Among compounded-focused services, offerings such as Medvi weight loss advertise a monthly membership with prescribing handled by a licensed clinician, which is the structure to confirm before comparing any two headline prices.
The programs worth avoiding are the ones that bury the titration price, obscure whether a clinician actually reviews the case, or present a compounded product as equivalent to the brand. That last move is not just marketing spin. Guidance on managing type 2 diabetes and obesity treats the approved agents as the reference standard for a reason, and blurring that line in a sales pitch is a warning sign.
Key takeaways
- The cheapest programs are cheap because they dispense compounded, non FDA-approved medication.
- The advertised entry price rarely survives dose increases, so rank by the sustainable monthly cost.
- Tirzepatide and semaglutide differ in results, so a lower price on a weaker molecule is not a bargain.
- Confirm the medication source and that a licensed clinician reviews the case before comparing prices.
See also: How Machine Learning Is Making the Future of Tech Smarter
Frequently asked questions
What does a telehealth weight-loss program actually cost per month?
It ranges widely. Compounded programs often advertise flat monthly prices in the low hundreds, while brand medication through a program can run well above a thousand dollars a month before any insurance or manufacturer self-pay price applies. The medication route drives the number more than the platform does.
Are the low advertised prices the real price?
Often only for the first month or the lowest dose. Many programs raise the price as the dose increases, add a membership or consult fee, or require a longer prepaid plan to hit the headline number. The sustainable monthly cost is what matters.
Is compounded medication from these programs FDA-approved?
No. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies and are not FDA-approved products. They may use the same active molecule as the brands but have not been through the approval process behind the published trials.
Do Medvi reviews reflect the total cost or just the medication?
Reviews often focus on the advertised entry price and customer service, not the full cost across dose increases or the difference between compounded and brand products. Read the pricing terms and the source of the medication before trusting a headline figure.
What should be checked before signing up for any program?
Whether the medication is a brand product or compounded, how the price changes as the dose increases, and whether a real licensed clinician reviews the case. Those three answers explain most of the difference between programs.